Senologie - Zeitschrift für Mammadiagnostik und -therapie, Table of Contents Senologie - Zeitschrift für Mammadiagnostik und -therapie 2016; 13(01): 26-33DOI: 10.1055/s-0042-103462 Übersicht © Georg Thieme Verlag KG Stuttgart · New York Zielgerichtete Therapie des HER2-positiven metastasierten Mammakarzinoms A. Rody Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter Schlüsselwörtermetastasiertes Mammakarzinom - HER2‑gerichtete Behandung - Expressionsprofie - AGO‑Empfehung - Trastuzumab - Pertuzumab - Trastuzumab Emtansin - Lapatinib Full Text References Literatur 1 Gesellschaft der epidemiologischen Krebsregister in Deutschland, Robert Koch-Institut. Krebs in Deutschland 2009/2010. 9. Aufl.. Berlin: RKI; 2013 2 Liedtke C, Rody A, Gluz O et al. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Res Treat 2015; 3 Harbeck N, Würstlein R. Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: Evidence and clinical considerations. Drugs 2013; 73: 1665-1680 4 Dowsett M, Harper-Wynne C, Boeddinghaus I et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61: 8452-8458 5 Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22: 1736-1747 6 Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182 7 Cheang MC, Chia SK, Voduc D et al. Ki67 Index, HER status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750 8 Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145 9 Goldhirsch A, Gelber RD, Piccard-Gebhart MJ et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013; 382: 1021-1028 10 Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119 11 Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791 12 Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2011; 29: e458 13 Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Leitlinien der AGO Kommission Mamma; Version 2015.1D. Online: http://www.ago-online.de Stand: 28.02.2015 14 Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 2009; 27: 5838-5847 15 Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290 16 Blackwell K, Miles D, Gianni L et al. Primary results from EMILIA, a phase 3 study of trastuzumab emtansin (T-DM1) vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. ASCO JCO 2012; 30: LBA1 17 Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-471 18 Swain SM, Baselga J, Kim SB et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734 19 Fachinformation Perjeta®, Stand: März 2015. 20 Ewer M, Baselga J, Clark E et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. ASCO JCO 2012; 30 (15s) 533 21 Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274 22 Slamon D, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792 23 Fachinformation Herceptin® i. v., Stand: April 2015. 24 Fachinformation Tyverb® 250 mg Filmtabletten, Stand: Juli 2013. 25 Osborne CK, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s-870s 26 Massarweh S, Osborne CK, Jiang S et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER2/neu-positive breast cancer. Cancer Res 2006; 66: 8266-8273 27 Witters LM, Kumar R, Chinchilli VM et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997; 42: 1-5 28 Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935 29 Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537 30 Huober J, Fasching PA, Barsoum M et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – results of the eLEcTRA trial. Breast 2012; 21: 27-33 31 Johnston S, Pippen Jr J, Pivot X. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postemenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546 32 Information der Arzneimittelkommission der Deutschen Ärzteschaft (AkdÄ): Tyverb® (Lapatinib). Stand: 03. 12. 2010. 33 Blackwell K, Burstein HJ, Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012; 30: 2585-2592 34 Fachinformation Kadcyla®, Stand: Oktober 2014. 35 Giordano SH, Temin S, Kirshner JJ et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 2078-2099 36 Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743 37 Cameron D, Casey M, Oliva C et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15: 924-934 38 Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648 39 Blackburn E, Zona S, Murphy ML et al. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines. Breast Cancer Res Treat 2012; 134: 53-59 40 Rodon J, Dienstmann R, Serra V et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013; 10: 143-153 41 Paplomata E, OʼRegan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 2014; 6: 154-166 42 Garber K. Targeting mTOR: something old, something new. J Natl Cancer Inst 2009; 101: 288-290 43 Ernst B, Anderson KS. Immunotherapy for the treatment of breast cancer. Curr Oncol Rep 2015; 17: 5
